Since the initial phase, the AnxA12–26 was able to reduce the expression of IL-1β, INF-γ, IL-6, TNF-α, and IL-17, corroborating studies with in vivo and in vitro models of retina autoimmune disease and uveitis in rodents and human (Girol et al., 2013; Yazid et al., 2015; Cardin et al., 2017). Here, IL17A is linked to autoimmune retinopathy.